New York State Common Retirement Fund’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33.6K | Hold |
28,015
| – | – | ﹤0.01% | 2921 |
|
|
2025
Q4 | $27.5K | Hold |
28,015
| – | – | ﹤0.01% | 3041 |
|
|
2025
Q3 | $35.3K | Hold |
28,015
| – | – | ﹤0.01% | 3026 |
|
|
2025
Q2 | $31.4K | Hold |
28,015
| – | – | ﹤0.01% | 3054 |
|
|
2025
Q1 | $22.1K | Hold |
28,015
| – | – | ﹤0.01% | 2958 |
|
|
2024
Q4 | $46.2K | Hold |
28,015
| – | – | ﹤0.01% | 2875 |
|
|
2024
Q3 | $98.1K | Hold |
28,015
| – | – | ﹤0.01% | 2592 |
|
|
2024
Q2 | $91.9K | Buy |
28,015
+20
| +0.1% | +$88 | ﹤0.01% | 2904 |
|
|
2024
Q1 | $205K | Sell |
27,995
-30
| -0.1% | -$186 | ﹤0.01% | 2423 |
|
|
2023
Q4 | $105K | Sell |
28,025
-168
| -0.6% | -$397 | ﹤0.01% | 2732 |
|
|
2023
Q3 | $59.8K | Buy |
28,193
+286
| +1% | +$947 | ﹤0.01% | 2960 |
|
|
2023
Q2 | $133K | Sell |
27,907
-76
| -0.3% | -$419 | ﹤0.01% | 2669 |
|
|
2023
Q1 | $160K | Sell |
27,983
-42,945
| -61% | -$259K | ﹤0.01% | 2685 |
|
|
2022
Q4 | $716K | Sell |
70,928
-4,466
| -6% | -$83.9K | ﹤0.01% | 2143 |
|
|
2022
Q3 | $1.69M | Buy |
75,394
+6,486
| +9% | +$187K | ﹤0.01% | 1697 |
|
|
2022
Q2 | $1.71M | Buy |
68,908
+664
| +1% | +$18.3K | ﹤0.01% | 1743 |
|
|
2022
Q1 | $2.65M | Buy |
68,244
+5,910
| +9% | +$229K | ﹤0.01% | 1604 |
|
|
2021
Q4 | $3.65M | Buy |
62,334
+4,386
| +8% | +$249K | ﹤0.01% | 1453 |
|
|
2021
Q3 | $3.44M | Sell |
57,948
-22,819
| -28% | -$1.79M | ﹤0.01% | 1471 |
|
|
2021
Q2 | $7.01M | Buy |
80,767
+7,322
| +10% | +$590K | 0.01% | 1186 |
|
|
2021
Q1 | $6.06M | Buy |
73,445
+8,845
| +14% | +$847K | 0.01% | 1177 |
|
|
2020
Q4 | $5.87M | Buy |
64,600
+3,400
| +6% | +$211K | 0.01% | 1195 |
|
|
2020
Q3 | $2.45M | Buy |
61,200
+3,700
| +6% | +$129K | ﹤0.01% | 1470 |
|
|
2020
Q2 | $1.97M | Buy |
57,500
+2,900
| +5% | +$86.4K | ﹤0.01% | 1541 |
|
|
2020
Q1 | $1.21M | Hold |
54,600
| – | – | ﹤0.01% | 1645 |
|
|
2019
Q4 | $1.07M | Buy |
54,600
+1,000
| +2% | +$15.9K | ﹤0.01% | 1923 |
|
|
2019
Q3 | $832K | Hold |
53,600
| – | – | ﹤0.01% | 2073 |
|
|
2019
Q2 | $1.09M | Sell |
53,600
-38,690
| -42% | -$697K | ﹤0.01% | 1966 |
|
|
2019
Q1 | $1.62M | Buy |
92,290
+39,890
| +76% | +$630K | ﹤0.01% | 1714 |
|
|
2018
Q4 | $672K | Hold |
52,400
| – | – | ﹤0.01% | 2134 |
|
|
2018
Q3 | $854K | Hold |
52,400
| – | – | ﹤0.01% | 2178 |
|
|
2018
Q2 | $594K | Buy |
52,400
+11,900
| +29% | +$131K | ﹤0.01% | 2377 |
|
|
2018
Q1 | $395K | Hold |
40,500
| – | – | ﹤0.01% | 2455 |
|
|
2017
Q4 | $247K | Hold |
40,500
| – | – | ﹤0.01% | 2656 |
|
|
2017
Q3 | $160K | Hold |
40,500
| – | – | ﹤0.01% | 2881 |
|
|
2017
Q2 | $131K | Buy |
+40,500
| New | +$155K | ﹤0.01% | 3029 |
|
Other funds holding FATE
RG
VCM
VPM
JJ
New York State Common Retirement Fund's FATE Position: Q1 2026 in Review
New York State Common Retirement Fund held its Fate Therapeutics (FATE) position steady in Q1 2026 at 28,015 shares worth $33.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2921.
New York State Common Retirement Fund first reported a position in FATE in Q2 2017 and has held it in 36 quarters since. The position peaked at $7.01M in Q2 2021. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.
- New York State Common Retirement Fund held 28,015 shares of Fate Therapeutics worth $33.6K as of Q1 2026.
- New York State Common Retirement Fund left its Fate Therapeutics share count unchanged in Q1 2026.
- Fate Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q1 2026, its #2921 holding.
- New York State Common Retirement Fund first reported a position in Fate Therapeutics in Q2 2017 and has held it in 36 quarters since.
- New York State Common Retirement Fund's Fate Therapeutics position peaked at $7.01M in Q2 2021.
- 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.
Based on New York State Common Retirement Fund's 13F filing for Q1 2026, filed 6 May 2026.